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To the Editor: 
 
Dr. Graham et al reported their research on the comparative effectiveness of warfarin 
and Nonvitamin K antagonist oral anticoagulants (NOACs) amongst patients with 
nonvalvular atrial fibrillation. This real-world study was based on claims data (US 
Medicare).1 The authors concluded that dabigatran and apixaban were associated with 
a more favorable benefit−harm profile than rivaroxaban in standard-dose NOAC 
users. 
 
We also note Dr. Graham’s previous work in JAMA Internal Medicine 2016.2 This 
study enrolled the Medicare nonvalvular atrial fibrillation patients who initiated 
dabigatran or rivaroxaban for stroke prevention from November 2011 to June 2014. 
Data for the recent paper were taken from October 2010 to September 2015, and it 
seems the two studies may have some overlap, because they have similar 
inclusion/exclusion criteria and results for the comparison between dabigatran and 
rivaroxaban. Can the authors to clarify the differences between current and 2016 
paper? For example, have identical covariates had been used in propensity score (PS) 
models? Did the PS model selection perform in the same dataset involving outcome 
data in it?3 The authors mention both 1:1 PS matching and stabilized inverse 
probability weighting (IPW) in the current analysis; estimated treatment effects can 
vary greatly between different PS methods using the same data.4 
 
The observed effect size was relatively small in the recent report, with weighted event 
rates of intracranial hemorrhage were 3.3 and 4.8 per 1,000 person-years for 
dabigatran and apixaban, respectively. The between group difference was statistically 
significant (95% confidence interval of hazard ratio excluded 1.0). We performed a 
power analysis with the assumed between group effect size (0.15% ≈ (4.8-3.3)/1,000) 
under different sample size scenarios (see Table 1). The current study (N=86,198 for 
dabigatran and N=73,039 for apixaban) seems over-powered to show a statistically 
significant between group difference which may not be clinical relevant. The dramatic 
decrease in the number at risk among the Kaplan-Meier plots should also be noted as 
it indicates that majority of the patients contributed very short-term follow-up 
information. 
 
In conclusion, real-world data can help us to compare different NOACs for 
effectiveness or safety, but the transparency of the analysis process and validity of the 
statistical method are paramount. The effect size for a specific intervention from an 
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